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Abstract
Background: In early breast cancer, the optimal technique for sentinel lymph node biopsy (SLNB) is the combined technique (radioisotope 
and Patent Blue V) which achieves high identification rates. Despite this, many centres have decided to stop using blue dye due to blue-
dye-related complications (tattoo, anaphylaxis). We evaluated the SLNB identification rate using the combined technique with and without 
Patent Blue V and the blue-dye-related complication rates.
Methods: Clinical and histological data were analysed on patients undergoing SLNB between March 2014 and April 2015. SLNB was 
performed following standard hospital protocols using the combined technique.
Results: A total of 208 patients underwent SLNB and 160 patients (342 nodes) with complete operation notes were available for final 
analysis. The identification rate with the combined technique was 98.8% (n = 158/160), with blue dye alone 92.5% (n = 148/160) and with 
radioisotope alone 97.5% (n = 156/160). A total of 76.9% (263/342) of nodes were radioactive and blue, 15.5% (53/342) only radioactive 
and 2.3% (8/342) only blue, 5.3% (18/342) were neither radioactive nor blue. No anaphylactic reactions were reported and blue skin stain-
ing was reported in six (3.8%) patients.
Conclusion: The combined technique should continue be the preferred technique for SLNB and should be standardised. Radioisotope 
alone (but not blue dye alone) has comparable sentinel node identification rates in experienced hands. National guidelines are required 
to optimise operative documentation.
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Introduction
In early breast cancer, sentinel lymph node biopsy (SLNB) is the preferred method for axillary staging [1–2]. SLNB involves identification 
and excision of the first lymph node(s) that receive lymphatic drainage from the primary breast tumour [3]. SLNB spares patients with pre-
operative negative nodes a more invasive axillary clearance operation and possible side-effects such as lymphedema, seroma, numbness, 
wound infection, reduced shoulder movement, and chronic pain [3–4].
The combined technique using both radioactive TcM99m and blue dye is the current golden standard for SLNB [5–6]. Identification rates of 
96–97% were achieved in the AMAROS [3] and ALMANAC trials [7]. It is well known that use of the combination of radioisotope and blue 
dye is significantly better than the two tracers in isolation [7–9].
Despite the recognised superiority of the dual technique over radioisotope alone, many centres have decided to stop using blue dye due to 
blue-dye-related complications (tattoo, anaphylaxis) or lack of licensing for blue dyes [9–13]. We evaluated the SLNB identification rate in 
experienced hands using the combined technique with and without Patent Blue V and the blue-dye-related complication rates.
Methods
Clinical and histological data were evaluated on patients undergoing SLNB between March 2014 and April 2015. This study was approved 
by the Clinical Review Board (ref 5320). 
Inclusion criteria
All patients who underwent SLNB for newly diagnosed breast cancer were included. In the case of a bilateral SLNB, only the side with the 
highest grade, largest primary tumour size or most involved nodes was included to avoid confounding variables.
Exclusion criteria
Patients were excluded if there was no procedure description available in operative or pathology notes, if only an injection of radioisotope 
or Patent Blue V was administered, or if the colour or radioactivity within nodes was not documented. 
SLNB procedure
All SLNB procedures were performed using radioisotope, Patent Blue V and a scrubbed consultant surgeon. Patients scheduled to undergo 
SLNB in the Breast Unit at Guy’s and St. Thomas’ NHS Foundation Trust were injected with radioisotope on the morning of surgery either 
at the Nuclear Medicine Department or in Day Surgery Unit. Prior to surgery, Patent Blue V was injected peri-areolarly on table followed 
by a massage of the injection site. During SLNB, the surgeon used a gamma probe to detect the radioisotope and visually identified blue 
nodes. Any nodes with a count of 10% or more of the highest node count were excised. Beyond four nodes, surgeons excised additional 
nodes only at their discretion and noted the background count on completion. Palpable nodes felt during the procedure were also removed. 
For every excised node, the gamma probe was used to determine the radioactivity of nodes ex vivo. Operation notes included the amount 
of Patent Blue V injected, amount of nodes excised and if these nodes were blue and/or radioactive. A successful SLNB was defined as a 
procedure in which at least one true sentinel node was identified to be either blue and/or radioactive.
Histopathology
All excised SLN’s were sent for histopathological evaluation in accordance with national protocols. Nodes were reported as either normal 
or involved containing isolated tumour cells (ITC) (≤ 0.2 mm), micrometastases (> 0.2 and ≤ 2.0 mm) or macrometastases (> 2.0 mm). The 
size of the largest deposit was also reported by the pathologist.
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Statistical analysis
To statistically determine whether SLNB with Patent Blue V provides a non-inferior identification rate compared to the combined technique, 
a sample size calculation was performed. With an identification rate for the combined technique of p = 0.97, we were prepared to accept 
non-inferiority with a margin of δ = 0.05. The probability that the addition of radioactivity results in finding new nodes is r0 = kδ with k = 0.2. 
With 90% power and a 95% one-sided confidence level, zα is the standard normal variate value corresponding to the test size, zα = 1.6449 
and zβ the variate corresponding to the test power, zβ = 1.2816. Using the following formula gives a sample size of N = 148 patients.
N = 
({δ(1–δ)}1/2zα + {r0(1–r0)}
1/2zβ)
2
(δ – r0)
2
A non-inferiority test was performed to define whether the blue dye technique alone is non-inferior to the combined technique using 
δ = 0.05 and p the identification rate of the combined technique. The probability of detecting a node with blue dye or with radioisotope alone 
should not be lower than p-δ. [14–15]
To evaluate potential differences in sentinel node identification with different tumour size and volume of blue dye, we performed an 
independent t-test. For tumour grade, lymph node status, the presence of lymphovascular invasion, ER/HER2 status, and surgeon’s 
experience, we performed a crosstab and Fisher’s exact test. We repeated the analysis for sentinel node identification with the combined 
technique, radioisotope alone, and blue dye alone. 
Results
A total of 208 patients underwent SLNB between March 2014 and April 2015. In the 48 patients who were excluded, operation notes were 
incomplete in 38 patients (18.3%) and operation notes were missing in eight patients (3.8%). One patient (0.5%) was excluded because 
she only received Patent Blue V and one patient (0.5%) only received radioisotope. A total of 160 patients in which 342 nodes (range 1–6 
nodes) removed were available for final analysis. Patient and tumour characteristics are tabulated in Table 1.
SLNB procedure
About 78.8% (126/160) procedures were performed by specialised breast surgeons who have over 10 years of experience and 21.2% 
(34/160) were performed by fellows specialised in breast surgery. 
In 80 cases (50.0%), SLNB’s were performed on the left and 80 cases (50.0%) on the right. There were 12 cases (7.5%) of bilateral 
SLNB. SLNB was performed in combination with a mastectomy in 47 cases (29.4%), wide local excision (WLE) in 89 cases (55.7%), 
and re-excision in five cases (3.1%). In 19 cases (11.9%), an SLNB alone was performed.
Volume of Patent Blue V dye injected
In 24 cases (15.0%), 1.0 ml of Patent Blue V dye was injected, 2.0 ml was injected in 70 cases (43.8%) and the volume of injected Patent 
Blue V dye was not documented in 66 cases (41.2%). All 1.0 ml injections were not diluted apart from one which was diluted with 2.0 ml of 
saline. About 40% (28/70) of 2.0 ml injections were not diluted and 60% (42/70) were diluted with 3.0 ml of saline.
Identification rates
The sentinel node identification rate with the combined technique was 98.8% (n = 158/160), with blue dye alone 92.5% (n = 148/160) and 
with radioisotope alone 97.5% (n = 156/160) (Table 2a). In two patients (1.3%), the SLNB procedure failed to identify a sentinel node and 
an axillary node clearance was undertaken. The probability of detecting nine nodes or fewer (158–148) is 0.82 which does not meet the 
δ = 0.05, and therefore, the hypothesis of inferiority cannot be rejected for blue dye alone.
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Table 1. Patient and tumour characteristics.
Variable Number of patients (%)
Type of surgery Wide local excision
Mastectomy
Re-excision
Sentinel node only
89 (55.7%)
47 (29.4%)
5 (3.1%)
19 (11.9%)
Tumour size Mean ± SD (range) 18.9 ± 13.0 mm 
(0–75 mm)
Blue dye injected 1.0 ml
2.0 ml
NR
24 (15.0%)
70 (43.8%)
66 (41.2%)
Tumour grade 1
2
3
NR
14.4% (n = 23)
41.9% (n = 67)
36.3% (n = 58)
7.5% (n = 12)
ER status +
-
NR
78.8% (n = 126)
18.8% (n = 30)
2.5% (n = 4)
HER 2 status +
-
NR
14.4% (n = 23)
78.8% (n = 126)
6.9% (n = 11)
Presence of  
lymphovascular 
invasion
+
-
NR
23.1% (n = 37)
68.1% (n = 109)
8.8% (n = 14)
Table 2. Identification rate (a) per patient and (b) per node.
(a)
Blue dye n (%)
Total n (%)
Yes No
Radioactive
n (%)
Yes 146 (91.3%) 10 (6.3%) 156 (97.5%)
No 2 (1.3%) 2 (1.3%) 4 (2.5%)
Total n (%) 148 (92.5%) 12 (7.5%) 160 (100%)
(b)
Blue dye n (%)
Total n (%)
Yes No
Radioactive
n (%)
Yes 263 (79.0%) 53 (15.9%) 316 (94.9%)
No 8 (2.4%) 9 (2.7%) 17 (5.1%)
Total n (%) 271 (81.4%) 62 (18.6%) 333 (100%)
The extra number of nodes detected by radioisotope was 6.3% (CI = 95% (0.03, 0.11)) using the normal approximation of Agresti and Coull 
[16]. The combined technique therefore has a probability of 98.9% of identifying a node (CI = 95% (0.955, 0.995)), making it consistent with 
the results of the ALMANAC and AMAROS trials [16].
An independent t-test found no statistically significant difference in sentinel node identification between patients with different tumour size 
and volume of blue dye injected. For tumour grade, lymph node status, the presence of lymphovascular invasion, ER/HER2 status and 
surgeon’s experience, Fisher’s exact test found no statistically significant differences with sentinel node identification. 
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Excised nodes
In 158 patients who underwent successful SLNB, a total of 333 sentinel lymph nodes were excised, a mean of 2.1 nodes per patient. One 
node was excised in 47 patients, two nodes in 68 patients, three nodes in 25 patients, four nodes in 16 patients, five node in one patient 
and six nodes in one patient. These nodes were both radioactive and blue in 263 nodes (79.0%), only radioactive in 53 nodes (15.9%), only 
blue in eight nodes (2.4%) and neither radioactive nor blue in nine nodes (2.7%) (Table 2b). 
The patients with sentinel lymph nodes not detected by blue dye were injected with 1 ml of blue dye (9 patients, 11 nodes), 2 ml (20 patients, 
30 nodes), or the amount was not mentioned (7 patients, 12 nodes). Patients with nodes not detected by either blue dye or radioisotope 
were injected with 1ml of blue dye (1 patient, 1 node), 2 ml (3 patients, 3 nodes) or this was not mentioned (4 patients, 5 nodes). 
The two patients with a failed SLNB had nine nodes excised after injection of 2 ml blue dye (1 patient, 4 nodes) or this was not mentioned 
(1 patient, 5 nodes).
Histopathology
On histopathological examination, 35 patients (16.8%) had involved lymph nodes, 15 patients (9.4%) had micrometastases and 20 patients 
(12.5%) had macrometastases (Table 2a). In these 35 patients with involved nodes, a total of 45 involved nodes were excised, two nodes 
(0.6%) with ITC, 18 nodes (5.3%) with micro-metastases and 25 nodes (7.3%) with macrometastases (Table 3a). A further nine patients 
(5.6%) had lymph nodes that contained nine (2.6%) ITCs.
Of 18 nodes with micrometastasis, 15 (83.3%) were both radioactive and blue and three (16.7%) were only radioactive. Of 25 nodes 
with macro-metastases, 18 nodes (72.0%) were both radioactive and blue, six nodes (24.0%) only radioactive and one node (4.0%) 
only blue (Table 3b). Therefore, the false-negative rate for blue dye was 21.4% (9/42 involved nodes) and for radioisotope 2.9% (1/34 
involved nodes).
Complication rate
Post-operative complications were seroma (n = 33), haematoma (n = 6), breast oedema (n = 2), infection (n = 2), erythema (n = 1), reduced 
shoulder movement (n = 1), pain (n = 1), a candida infection (n = 1) and an undocumented complication (n = 1).
Table 3. Histopathological outcome (a) per patient and per sentinel lymph 
node and (b) sentinel lymph node identification of involved nodes using 
radiosiotope or Patent Blue V.
(a)* Per patient n (%) Per sentinel lymph node n (%)
Normal 116 (72.5%) 288 (84.2%)
ITC 9 (5.6%) 11 (3.2%)
Micro 15 (9.4%) 18 (5.3%)
Macro 20 (12.5%) 25 (7.3%)
*ITC: isolated tumour cells, micro: micro-metastases, macro: macro-metastases.
(b)*
Radioactive and 
blue n (%)
Radioactive 
alone n (%)
Blue alone 
n (%)
None 
n (%)
ITC 11 (100%) 0 0 0
Micro 15 (83.3%) 3 (16.7%) 0 0
Macro 18 (72.0%) 6 (24.0%) 1 (4.0%) 0
*ITC: isolated tumour cells, micro: micrometastases, macro: macrometastases.
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Blue staining of the skin was reported in 3.8% (n = 6/160) of patients which successfully underwent SLNB and no anaphylactic reactions 
related to blue dye were reported.
Discussion
The sentinel node identification rate of the combined technique was 98.8% in our study, in line with the identification rates reported in the 
most recent ALMANAC and AMAROS trials [3, 7]. The identification rates for blue dye and radioisotope alone were 93.1% and 97.5%, 
respectively. Radioisotope alone does not meet the a priori non-inferiority criteria and is thus non-inferior to the combined technique. 
However, in a few patients, sentinel nodes are still identified with blue dye alone, suggesting that the use of two different dyes increases 
sentinel node identification. The use of an additional tracer reduces the false-negative rate of sentinel node biopsy [10]. However, it might 
be possible to obtain the same SLNB false-negative rate by administering two radioisotope injections (an additional injection instead of blue 
dye) rather than one [17]. The combined technique should therefore remain the standard of care at present. No blue-dye-related serious 
adverse events were described, and six cases of blue dye staining were described, suggesting the blue dye staining is under-reported as 
it is often asymptomatic.
Variation was observed in the amount of blue dye administered. Furthermore, lack of adequate operative documentation during surgery 
was observed in 38 patients (18.3%). Documentation of retrieval of blue or radioactive nodes confirms if the SLNB procedure was success-
fully completed. There are currently no national (or international) guidelines describing the minimal data set required for the documentation 
of SLNB procedures. SLNB carries a 6–10% false-negative rate when performed using the standard combined technique, it is likely to be 
higher if the combined technique is not used with consequently lower identification rates. In this study, the false negative rates for blue dye 
and radioisotope were 21.4% and 2.9%, respectively. However, no axillary node clearance was performed, to be able to obtain the correct 
false-negative rate for both techniques. In order to be able to audit SLNB identification rates, it is essential to know the number of nodes 
removed, their colour and radioactivity count. Guidelines are needed to ensure standardised administration of blue dye and adequate 
documentation of these procedures, including the type, amount, and dilution of tracers used.
Blue dye causes a tattoo at the site of injection and carries a 0.6% risk of anaphylaxis. Complications due to blue dye may be under-
reported due to inadequate documentation. In this study, a blue tattoo was only reported in 3.8% (six patients) suggesting this is signifi-
cantly under-reported as it is often asymptomatic. Furthermore, the blue staining was only reported up to three weeks after SLNB, without 
documentation of resolution. With the increased number of patients suitable for SLNB, it is important to reduce the risk of blue-dye-related 
complications. In order to understand the impact of the issue, correct documentation is necessary. Therefore, there should be greater 
emphasis on standardisation of surgical techniques.
With respect to nodal involvement the combined technique should be used since if only the radioisotope or blue dye techniques are used 
alone, involved nodes would have been missed (Table 3). The limitation of this study are the wide ranges of blue dye injection volumes 
and this could potentially impact on the identification rate. However, no statistically significant differences were found between sentinel 
node identification and volume of blue dye used and other factors, such as tumour size, tumour grade, lymph node status, the presence of 
lymphovascular invasion, ER/HER2 status, and surgeon’s experience. This is most likely due to the very small number of patients with no 
blue or radioactive nodes identified as the blue dye, radioisotope and the combined techniques have high identification rates.
In the search for new SLNB techniques, it will be difficult to find a technique with an identification rate superior to that of the combined tech-
nique in view of its very high identification rate. However, if we can develop a single agent or device that can accomplish the same level of 
accuracy and rule out the use of radioisotopes, it is likely that the combined technique will be replaced. Currently, several new techniques 
are under investigation, including the magnetic technique, using superparamagnetic nanoparticles and a hand-held magnetometer, show-
ing an identification rate between 94.4% and 98.5% [12, 13, 18, 19] and a fluorescent technique, using indocyanine green and fluorescent 
cameras showing an identification rate between 73.8% and 100% [19–26]. These techniques are promising, but need further clinical evalu-
ation. A randomised controlled trial comparing these outcomes against the combined technique would benefit these techniques. However, 
any randomised controlled trial will compare the new technique against the standard and it is important that the combined technique is 
used in a standardised way. 
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Conclusion
The combined technique should continue to be the preferred technique for SLNB and should be standardised. Radioisotope alone (but 
not blue dye alone) has comparable sentinel node identification rates in experienced hands. National guidelines are required to optimise 
operative documentation.
List of abbreviations
ALND Axillary lymph node dissection
SLNB Sentinel lymph node biopsy
WLE Wide local excision
ITC Isolated tumour cells
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